Opinion|Videos|June 9, 2023
Emerging Evidence on the Treatment of Obesity
In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.
Advertisement
Episodes in this series
1:20 Obesity-associated metabolic disturbances
5:37 When to start medication for obesity
8:28 Metabolic pathways leading to weight gain
13:19 Long-term impact of weight fluctuations
16:07 GLP-1 agonists for weight loss
20:26 Insurance coverage for anti-obesity medications (AOMs)
24:50 Combining lifestyle changes with AOMs
26:27 ‘Super-responders’ to GLP-1 agonist therapies
30:51 Non-responders to GLP-1 agonist therapies
37:28 Comprehensive approach to weight management
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
4
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
5